HighTower Advisors
BPMC

HighTower Advisors’s Blueprint Medicines BPMC Stock Holding History

HighTower Advisors’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-26,404
Closed -$1.16M – 3427
2022
Q4 		$1.16M Buy
+26,404
New +$1.27M ﹤0.01% 1598
2022
Q3 		– Sell
-11,167
Closed -$565K – 3176
2022
Q2 		$565K Buy
+11,167
New +$654K ﹤0.01% 1971

Other funds holding BPMC

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

HighTower Advisors's BPMC Position: Q1 2023 in Review

HighTower Advisors sold out of Blueprint Medicines (BPMC) in Q1 2023, closing a stake of 26,404 shares — an estimated $1.16M sold.

HighTower Advisors first reported a position in BPMC in Q2 2022 and held it in 2 quarters. The position peaked at $1.16M in Q4 2022. 214 funds tracked by Wall St. Rank hold BPMC as of Q1 2023.

  • HighTower Advisors reported no remaining Blueprint Medicines position as of Q1 2023 after selling out during the quarter.
  • HighTower Advisors sold 26,404 Blueprint Medicines shares in Q1 2023, an estimated $1.16M.
  • HighTower Advisors first reported a position in Blueprint Medicines in Q2 2022 and held it in 2 quarters.
  • HighTower Advisors's Blueprint Medicines position peaked at $1.16M in Q4 2022.
  • 214 funds tracked by Wall St. Rank held Blueprint Medicines as of Q1 2023.

Based on HighTower Advisors's 13F filing for Q1 2023, filed 12 May 2023.